US20040062800A1 - Sustained release pharmaceutical dosage forms with minimized ph dependent dissolution profiles - Google Patents

Sustained release pharmaceutical dosage forms with minimized ph dependent dissolution profiles Download PDF

Info

Publication number
US20040062800A1
US20040062800A1 US10/451,271 US45127103A US2004062800A1 US 20040062800 A1 US20040062800 A1 US 20040062800A1 US 45127103 A US45127103 A US 45127103A US 2004062800 A1 US2004062800 A1 US 2004062800A1
Authority
US
United States
Prior art keywords
composition
agent
dependent
cellulose
anagrelide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/451,271
Inventor
Beth Burnside
Rong-Kun Chang
Xiaodi Guo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Supernus Pharmaceuticals Inc
Original Assignee
Burnside Beth A.
Rong-Kun Chang
Xiaodi Guo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24981155&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20040062800(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Burnside Beth A., Rong-Kun Chang, Xiaodi Guo filed Critical Burnside Beth A.
Priority to US10/451,271 priority Critical patent/US20040062800A1/en
Publication of US20040062800A1 publication Critical patent/US20040062800A1/en
Assigned to SUPERNUS PHARMACEUTICALS, INC reassignment SUPERNUS PHARMACEUTICALS, INC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SHIRE LABORATORIES, INC
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid

Definitions

  • This invention relates to pharmaceutical compositions. More particularly, this invention relates to pharmaceutical compositions having a pH-independent or a minimized pH-dependent dissolution profile.
  • such composition includes at least one pharmaceutically active agent that has a pH dependent solubility profile, at least one non-pH-dependent sustained release agent, and at least one pH-dependent agent that increases the dissolution rate of the at least one pharmaceutically active agent at a pH in excess of 5.5.
  • the active agent(s) has (have) a solubility profile wherein the active agent(s) is (are) more soluble in an acidic medium than in a basic medium.
  • Compressed matrix tablets containing a basic drug often give a faster dissolution profile in simulated gastric fluid, having a pH about 1.0, than in simulated intestinal fluid (pH 6.8 to 7.4).
  • a pharmaceutical composition comprising at least one pharmaceutically active agent that is pH dependent, at least one non-pH dependent sustained release agent, and at least one pH-dependent agent that increases the rate of release of the at least one pharmaceutically active agent from the tablet at a pH in excess of 5.5, such as at least one organic acid that maintains an acidic micro-environment in the tablet.
  • Pharmaceutically active agents which are pH dependent and which may be included in the composition include, but are not limited to, weakly basic drugs and their salts that have higher solubilities at lower pH levels.
  • Such drugs include, but are not limited to, guanfacine hydrochloride, guanadrel sulfate, reserpine, anagrelide hydrochloride, propanolol, metoprolol, atenolol, timolol, erthyrthromycin, clonidine, chlorpheniramine, bromopheniramine, diltiazen, and scopolamine.
  • the pharmaceutically active agent is present in the composition in an amount of from about 0.1 wt, % to about 70 wt. %, preferably from about 1 wt. % to about 40 wt %.
  • the at least one pharmaceutically active agent is guanfacine hydrochloride.
  • the at least one pharmaceutically active agent is anagrelide hydrocholoride. It is to be understood, however, that the scope of the present invention is not to be limited to any particular pharmaceutically active agent.
  • Non-pH-dependent sustained release agents which may be included in the composition include, but are not limited to, ethylcellulose, cellulose acetate, vinyl acetatelvinyl chloride copolymers, acrylate/methacrylate copolymers, polyethylene oxide, hydroxypropyl methylcellulose, carrageenan, alginic acid and salts thereof, hydroxyethyl cellulose, hydroxypropyl cellulose, karaya gum, acacia gum, tragacanth gum, locust bean gum, guar gum, sodium carboxymethyl cellulose, methyl cellulose, beeswax, carnauba wax, cetyl alcohol, hydrogenated vegetable oils, and stearyl alcohol.
  • the at least one non-pH-dependent sustained release agent is present in the composition in an amount of from about 5 wt. % to about 50 wt. %, preferably from about 10 wt. % to about 30 wt. %. It is to be understood, however, that the scope of the present invention is not to be limited to any particular non-pH-dependent sustained release agents.
  • pH-dependent agents that increase the rate of release of the at least one pharmaceutically active agent from the tablet at a pH in excess of 5.5 include, but are not limited to, polymers that swell at a pH in excess of 5.5, and enteric agents, and/or agents that increase the solubility of the at least one pharmaceutically active agent at a pH greater than 5.5, by maintaining an acidic microenvironment in the tablet, e.g., an organic acid.
  • the at least one pH-dependent agent is present in the composition in an amount of from about 0.5 wt. % to about 40 wt. %, preferably from about 1 wt. % to about 20 wt. %.
  • Polymers that swell at a pH in excess of 5.5 include, but are not limited to, acrylic acid copolymers, sodium alginate, carrageenan, alginic acid, pectin, and sodium carboxymethyl cellulose.
  • Enteric agents include, but are not limited to, cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, polyvinyl acetate phthalate, methacrylic acid coplymers, cellulose acetate trimellitate, hydroxypropyl methylcellulose acetate, succinate, shellac, and zein.
  • Agents that increase the solubility of the at least one pharmaceutically active agent at a pH greater than 5.5 include, but are not limited to, organic acids.
  • organic acids maintain an acidic microenvironment in the tablet, and include, but are not limited to, citric acid, fumaric acid, tartaric acid, adipic acid, glucono delta-lactone, and malic acid.
  • composition of the present invention may further include other materials such as bulking agents, disintegrating agents, anti-adherants and glidants, lubricants, and binding agents.
  • Bulking agents include, but are not limited to, microcrystalline cellulose (eg., Avicel®, FMC Corp., Emcocel®, Mendell Inc.), mannitol, xylitol, dicalcium phosphate (eg. Emcompress, Mendell Inc.) calcium sulfate (eg.
  • the bulking agent may be present in the composition in an amount of from about 5 wt. % to about 90 wt. %, preferably from about 10 wt. % to about 50 wt. %.
  • Disintegrating agents which may be included in the composition include, but are not limited to, microcrystalline cellulose, starches, crospovidone (eg. Polyplasdone XL, International Specialty Products.), sodium starch glycolate (Explotab, Mendell Inc.), and crosscarmellose sodium (eg., Ac-Di-Sol, FMC Corp.).
  • the disintegrating agent may be present in the composition in an amount of from about 0.5 wt. % to about 30 wt %, preferably from about 1 wt. % to about 15 wt. %.
  • Antiadherants and glidants which may be employed in the composition include, but are not limited to, talc, corn starch, silicon dioxide, sodium lauryl sulfate, and metallic stearates.
  • the antiadherant or glidant may be present in the composition in an amount of from about 0.2 wt. % to about 15 wt. %, preferably from about 0.5 wt. % to about 5 wt. %.
  • Lubricants which may be employed in the composition include, but are not limited to, magnesium stearate, calcium stearate, sodium stearate, stearic acid, sodium stearyl fumarate, hydrogenated cotton seed oil (sterotex), talc, and waxes, including but not limited to, beeswax, carnuba wax, cetyl alcohol, glyceryl stearate, glyceryl palmitate, glyceryl behenate, hydrogenated vegetable oils, and stearyl alcohol.
  • the lubricant may be present in an amount of from about 0.2 wt. % to about 20 wt. %, preferably from about 0.5 wt. % to about 5 wt. %.
  • Binding agents which may be employed include, but are not limited to, polyvinyl pyrrollidone, starch, methylcellulose, hydroxypropyl methylcellulose, carboxymethyl cellulose, sucrose solution, dextrose solution, acacia, tragacanth and locust bean gum.
  • the binding agent may be present in the composition in an amount of from about 0.2 wt. % to about 10 wt. %, preferably from about 0.5 wt. % to about 5 wt. %.
  • compositions of the present invention may be made by a direct compression method, or by a wet granulation method.
  • the direct compression method the at least one pharmaceutically active agent and other ingredients are sieved through a stainless steel screen, such as a 40 mesh steel screen.
  • the sieved materials then are charged to a suitable blender, and blended for 10 minutes with an intensifier bar on for 3 minutes.
  • the blend then is compressed into tablets on a rotary press using appropriate tooling.
  • the compressed tablets may be coated, if desired.
  • the at least one pharmaceutically active agent and other ingredients are granulated with a granulating fluid (e.g., isopropyl alcohol, ethyl alcohol, and water) in a planetary mixer, high shear mixer, or fluidized bed granulator. Binding agents may be contained in the granulating fluid, or may be in the dry mix.
  • the wet granules are dried in an oven or fluidized bed dryer, and then sieved through a suitable screen to obtain free flowing granules.
  • the resulting granules were blended with a suitable lubricant and glidant, and the lubricated granules are compressed into tablets on a rotary press using appropriate tooling. If desired, a coating can be applied onto the compressed tablets.
  • the composition may be employed in treating an attention deficit disorder, or attention deficit with hyperactivity disorder.
  • the composition including guanfacine hydrochloride is administered to an animal, such as a mammal, including human and non-human primates, in an amount effective to treat the disorders mentioned hereinabove.
  • compositions of the present invention may be employed to treat a variety of diseases or disorders.
  • guanfacine hydrochloride When guanfacine hydrochloride is administered as part of a composition in accordance with the present invention, there is a reduction in the number of side effects associated with the administration of guanfacine hydrochloride, or a reduction in the likelihood of side effects associated with the administration of guanfacine hydrochloride.
  • a pharmaceutical composition comprising guafancine as an active agent and characterized in that said composition when administered to a patient produces less of the side effects usually associated with guafancine.
  • the side effects are chosen from Headache, Asthenia, Somnolence, Dizziness, Tacchycardia, Nausea, Pain Abdominal, Infect, Vomit, or Palpitations.
  • the side effects are chosen from Headache or Asthenia.
  • the composition may be employed in treating a variety of blood disorders, including, but not limited to, myeloproliferative blood disorders or MBDs, such as, for example, essential thrombocythemia, or ET, chronic myelogenous leukemia, or CML, polycythemia vera, or PV, and agnogenic myeloid metaplasia, or AMM.
  • MBDs myeloproliferative blood disorders
  • the composition including anagrelide may be administered to an animal, such as a mammal, including human and non-human primates, in an amount effective to treat such disorders.
  • the active agent anagrelide may be administered to a patient in an amount of from about 0.01 mg to 15 mg, preferably from about 0.1 mg to about 10 mg, more preferably from about 0.1 mg to about 5 mg and most preferably from about 0.5 mg to about 2 mg.
  • anagrelide may be administered to a patient in an amount of 0.5 mg four times a day, or 1 mg twice a day, for at least one week.
  • anagrelide is administered as part of a composition in accordance with the present invention, there is a reduction in the number of side effects associated with the administration of anagrelide, or a reduction of the likelihood of side effects associated with the administration of anagrelide.
  • composition comprising anagrelide as an active agent and characterized in that said composition when administered to a patient produces less of the side effects usually associated with anagrelide.
  • the side effects are chosen from Headache, Asthenia, Somnolence, Dizziness, Tacchycardia, Nausea, Pain Abdominal, Infect, Vomit, or Palpitations.
  • the side effects are chosen from Headache or Asthenia.
  • Formulations in accordance with the present invention, as well as control formulations, were prepared according to the direct compression described hereinabove.
  • guanfacine HCl and other ingredients were sieved through a 40 mesh steel screen.
  • the sieved materials then were charged into a Blendmaster blender (Patterson-Kelley Co.), and blended for 10 minutes with an intensifier bar on for 3 minutes.
  • the blends then are compressed into tablets on a rotary tablet press (Stokes-Merrill Corp., Model 512) using appropriate tooling
  • a Vankel dissolution tester (VanKel Industries, Edison, N.J.) was used for all dissolution studies. The apparatus was calibrated according to USP23. The dissolution in 0.1N hydrochloric acid (pH 1.2) or pH 6.8 phosphate buffer was tested using the paddle method (USP Apparatus II), employing 500 ml of dissolution medium at a temperature of 37° C. and an agitation rate of 50 rpm. Samples at specific time points were removed and filtered through a 35 ⁇ m filter. The filtered samples were kept in screw cap glass test tubes until analysis. An HPLC system comprised of an autosampler and a pump and a UV detector was used for sample analysis. 50 ⁇ l of the dissolution samples were injected directly on the HPLC C18 column using a mixture of acetonitrile and acetate buffer (20:80) as the mobile phase.
  • compositions of the present invention have improved dissolution profiles when compared with the control compositions.
  • Formulations in accordance with the present invention, as well as control formulations, were prepared according to the direct compression method described hereinabove.
  • guanfacine HCl and other ingredients were sieved through a 40 mesh steel screen.
  • the sieved materials then were charged into a Blendmaster blender (Patterson-Kelley Co.), and blended for 10 minutes with an intensifier bar on for 3 minutes.
  • the blends then are compressed into tablets on a rotary tablet press (Stokes-Merrill Corp., Model 512) using appropriate tooling
  • the solubility of anagrelide HCl in aqueous solutions in the pH range of 1 to 11.4 at 25° C. was determined.
  • the solubility-pH profile of anagrelide HCl is shown in FIG. 1. Below pH 3, the solubility increased as the pH decreased which is consistent with formation of a more soluble protonated form. At pH 0.96 the solubility was 236 mcg/mL. Above pH 4, the solubility was independent of pH and remained constant (ca. 1.2 mcg/mL) up to pH 8. Above pH 8, the solubility increased with increasing pH which is due to the ionization of the quinazoline moiety. The solubility at pH 11.4 was 992 mcg/mL.
  • Formulations I through IV were formulated according to the procedure described in Example 1, except that anagrelide HCl has been substituted for guanfacine HCl.
  • a Vankel dissolution tester (VanKel Industries, Edison, N.J.) was used for all dissolution studies. The apparatus was calibrated according to USP 23. The dissolution in 0.1N hydrochloric acid (pH 1.1) with 0.1% Tween 80 or pH 6.8 phosphate buffer with 0.1% Tween 80 was tested using the paddle method (USP Apparatus II), employing 900 ml of dissolution medium at a temperature of 37° C., and an agitation rate of 100 rpm. Samples at specific time points were removed and filtered through a 70 ⁇ m filter. The filtered samples were kept in screw cap glass test tubes until analysis.
  • Formulations V, VI, and VII which are modifications of Formulation IV of Example 2, include the following components as shown in Table 6 below.
  • Table 6 Formulation V
  • Formulation VI Component mg/tablet % mg/tablet % mg/tablet % mg/tablet %
  • Anagrelide HCl Monohydrate* 0.63 0.315 1.26 0.630 1.88 0.940 Polyethylene Oxide, 60 Mesh
  • Dibasic Calcium Phosphate Anhydrous
  • USP Flujicalin SG
  • Cellulose (Prosolv HD 90) USP Methacrylic Acid Copolymer
  • Glyceryl Behenate NF 17.56 8.780 17.56 8.780 17.
  • Formulations V, VI, and VII were prepared and processed into tablets according to the following procedure:
  • step 8 Pass the blend from step 8 through a 30-mesh screen using a Comil at the low speed setting and collect it in a polyethylene bag.
  • Formulations 1, 2, and 3 were prepared, which had the following components in the following amounts, as shown in Table 7 below.
  • TABLE 7 Amount, wt % Formulation Formulation Formulation Component 1 2 3 Anagrelide HCl, Monohydrate 0.61 0.61 0.61 Polyethylene Oxide 15.00 — 25.00 (Polyox TM WSR 301) Polyethylene Oxide, 60 Mesh, — 20.00 — NF (Polyox TM WSR N80) Dibasic Calcium Phosphate, 30.61 20.61 30.61
  • the purpose of this example was to assess the bioavailability of three anagrelide HCl extended release tablet formulationsFormulation 1Formulation 2Formulation 3, compared to an immediate release anagrelide HCl formulation (Agrylin®, Lot No. RPA 0002A), following a 1 mg dose, and to determine the safety and tolerability of the extended release formulations in healthy volunteers.
  • T max maximum concentration

Abstract

A pharmaceutical composition comprising at least one pharmaceutically active agent that is pH dependent, at least one non-pH dependent sustained release agent, and at least one pH dependent agent that increases the dissolution rate of the at least one pharmaceutically active agent at a pH in excess of 5.5. Such compositions have minimized pH-dependent dissolution profiles or pH-independent dissolution profiles.

Description

  • This invention relates to pharmaceutical compositions. More particularly, this invention relates to pharmaceutical compositions having a pH-independent or a minimized pH-dependent dissolution profile. In particular, such composition includes at least one pharmaceutically active agent that has a pH dependent solubility profile, at least one non-pH-dependent sustained release agent, and at least one pH-dependent agent that increases the dissolution rate of the at least one pharmaceutically active agent at a pH in excess of 5.5. The active agent(s) has (have) a solubility profile wherein the active agent(s) is (are) more soluble in an acidic medium than in a basic medium. [0001]
  • The rate at which a drug goes into solution when it is dissolved in a medium is proportional to the solubility of the drug in the medium. Many drugs have different solubilities at different pHs. These pH-dependent solubility differences lead to pH-dependent dissolution profiles. In general, pH-dependent dissolution is an undesirable product characteristic. [0002]
  • Compressed matrix tablets containing a basic drug often give a faster dissolution profile in simulated gastric fluid, having a pH about 1.0, than in simulated intestinal fluid (pH 6.8 to 7.4). [0003]
  • It is an object of the present invention to provide a pharmaceutical composition with a minimized pH dependent or a pH-independent dissolution profile. [0004]
  • In accordance with an aspect of the present invention, there is provided a pharmaceutical composition. The composition comprises at least one pharmaceutically active agent that is pH dependent, at least one non-pH dependent sustained release agent, and at least one pH-dependent agent that increases the rate of release of the at least one pharmaceutically active agent from the tablet at a pH in excess of 5.5, such as at least one organic acid that maintains an acidic micro-environment in the tablet. [0005]
  • Pharmaceutically active agents which are pH dependent and which may be included in the composition include, but are not limited to, weakly basic drugs and their salts that have higher solubilities at lower pH levels. Such drugs include, but are not limited to, guanfacine hydrochloride, guanadrel sulfate, reserpine, anagrelide hydrochloride, propanolol, metoprolol, atenolol, timolol, erthyrthromycin, clonidine, chlorpheniramine, bromopheniramine, diltiazen, and scopolamine. In general, the pharmaceutically active agent is present in the composition in an amount of from about 0.1 wt, % to about 70 wt. %, preferably from about 1 wt. % to about 40 wt %. In one embodiment, the at least one pharmaceutically active agent is guanfacine hydrochloride. In another embodiment, the at least one pharmaceutically active agent is anagrelide hydrocholoride. It is to be understood, however, that the scope of the present invention is not to be limited to any particular pharmaceutically active agent. [0006]
  • Non-pH-dependent sustained release agents which may be included in the composition include, but are not limited to, ethylcellulose, cellulose acetate, vinyl acetatelvinyl chloride copolymers, acrylate/methacrylate copolymers, polyethylene oxide, hydroxypropyl methylcellulose, carrageenan, alginic acid and salts thereof, hydroxyethyl cellulose, hydroxypropyl cellulose, karaya gum, acacia gum, tragacanth gum, locust bean gum, guar gum, sodium carboxymethyl cellulose, methyl cellulose, beeswax, carnauba wax, cetyl alcohol, hydrogenated vegetable oils, and stearyl alcohol. In general, the at least one non-pH-dependent sustained release agent is present in the composition in an amount of from about 5 wt. % to about 50 wt. %, preferably from about 10 wt. % to about 30 wt. %. It is to be understood, however, that the scope of the present invention is not to be limited to any particular non-pH-dependent sustained release agents. [0007]
  • pH-dependent agents that increase the rate of release of the at least one pharmaceutically active agent from the tablet at a pH in excess of 5.5 include, but are not limited to, polymers that swell at a pH in excess of 5.5, and enteric agents, and/or agents that increase the solubility of the at least one pharmaceutically active agent at a pH greater than 5.5, by maintaining an acidic microenvironment in the tablet, e.g., an organic acid. The at least one pH-dependent agent is present in the composition in an amount of from about 0.5 wt. % to about 40 wt. %, preferably from about 1 wt. % to about 20 wt. %. [0008]
  • Polymers that swell at a pH in excess of 5.5 include, but are not limited to, acrylic acid copolymers, sodium alginate, carrageenan, alginic acid, pectin, and sodium carboxymethyl cellulose. [0009]
  • Enteric agents include, but are not limited to, cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, polyvinyl acetate phthalate, methacrylic acid coplymers, cellulose acetate trimellitate, hydroxypropyl methylcellulose acetate, succinate, shellac, and zein. [0010]
  • Agents that increase the solubility of the at least one pharmaceutically active agent at a pH greater than 5.5 include, but are not limited to, organic acids. Such organic acids maintain an acidic microenvironment in the tablet, and include, but are not limited to, citric acid, fumaric acid, tartaric acid, adipic acid, glucono delta-lactone, and malic acid. [0011]
  • The composition of the present invention may further include other materials such as bulking agents, disintegrating agents, anti-adherants and glidants, lubricants, and binding agents. [0012]
  • Bulking agents include, but are not limited to, microcrystalline cellulose (eg., Avicel®, FMC Corp., Emcocel®, Mendell Inc.), mannitol, xylitol, dicalcium phosphate (eg. Emcompress, Mendell Inc.) calcium sulfate (eg. Compactrol, Mendell Inc.) starches, lactose, sucrose (Dipac, Amstar, and Nutab, Ingredient Technology), dextrose (Emdex, Mendell, Inc.), sorbitol, cellulose powder (Elcema, Degussa, and Solka Floc, Mendell, Inc.) The bulking agent may be present in the composition in an amount of from about 5 wt. % to about 90 wt. %, preferably from about 10 wt. % to about 50 wt. %. [0013]
  • Disintegrating agents which may be included in the composition include, but are not limited to, microcrystalline cellulose, starches, crospovidone (eg. Polyplasdone XL, International Specialty Products.), sodium starch glycolate (Explotab, Mendell Inc.), and crosscarmellose sodium (eg., Ac-Di-Sol, FMC Corp.). The disintegrating agent may be present in the composition in an amount of from about 0.5 wt. % to about 30 wt %, preferably from about 1 wt. % to about 15 wt. %. [0014]
  • Antiadherants and glidants which may be employed in the composition include, but are not limited to, talc, corn starch, silicon dioxide, sodium lauryl sulfate, and metallic stearates. The antiadherant or glidant may be present in the composition in an amount of from about 0.2 wt. % to about 15 wt. %, preferably from about 0.5 wt. % to about 5 wt. %. [0015]
  • Lubricants which may be employed in the composition include, but are not limited to, magnesium stearate, calcium stearate, sodium stearate, stearic acid, sodium stearyl fumarate, hydrogenated cotton seed oil (sterotex), talc, and waxes, including but not limited to, beeswax, carnuba wax, cetyl alcohol, glyceryl stearate, glyceryl palmitate, glyceryl behenate, hydrogenated vegetable oils, and stearyl alcohol. The lubricant may be present in an amount of from about 0.2 wt. % to about 20 wt. %, preferably from about 0.5 wt. % to about 5 wt. %. [0016]
  • Binding agents which may be employed include, but are not limited to, polyvinyl pyrrollidone, starch, methylcellulose, hydroxypropyl methylcellulose, carboxymethyl cellulose, sucrose solution, dextrose solution, acacia, tragacanth and locust bean gum. The binding agent may be present in the composition in an amount of from about 0.2 wt. % to about 10 wt. %, preferably from about 0.5 wt. % to about 5 wt. %. [0017]
  • The compositions of the present invention may be made by a direct compression method, or by a wet granulation method. In the direct compression method, the at least one pharmaceutically active agent and other ingredients are sieved through a stainless steel screen, such as a 40 mesh steel screen. The sieved materials then are charged to a suitable blender, and blended for 10 minutes with an intensifier bar on for 3 minutes. The blend then is compressed into tablets on a rotary press using appropriate tooling. The compressed tablets may be coated, if desired. [0018]
  • In the wet granulation method, the at least one pharmaceutically active agent and other ingredients are granulated with a granulating fluid (e.g., isopropyl alcohol, ethyl alcohol, and water) in a planetary mixer, high shear mixer, or fluidized bed granulator. Binding agents may be contained in the granulating fluid, or may be in the dry mix. The wet granules are dried in an oven or fluidized bed dryer, and then sieved through a suitable screen to obtain free flowing granules. The resulting granules were blended with a suitable lubricant and glidant, and the lubricated granules are compressed into tablets on a rotary press using appropriate tooling. If desired, a coating can be applied onto the compressed tablets. [0019]
  • When the pharmaceutically active agent is guanfacine hydrochloride, the composition may be employed in treating an attention deficit disorder, or attention deficit with hyperactivity disorder. The composition including guanfacine hydrochloride is administered to an animal, such as a mammal, including human and non-human primates, in an amount effective to treat the disorders mentioned hereinabove. [0020]
  • The compositions of the present invention may be employed to treat a variety of diseases or disorders. [0021]
  • When guanfacine hydrochloride is administered as part of a composition in accordance with the present invention, there is a reduction in the number of side effects associated with the administration of guanfacine hydrochloride, or a reduction in the likelihood of side effects associated with the administration of guanfacine hydrochloride. [0022]
  • In accordance with a further aspect of the present invention there is provided a pharmaceutical composition comprising guafancine as an active agent and characterized in that said composition when administered to a patient produces less of the side effects usually associated with guafancine. [0023]
  • In one embodiment the side effects are chosen from Headache, Asthenia, Somnolence, Dizziness, Tacchycardia, Nausea, Pain Abdominal, Infect, Vomit, or Palpitations. [0024]
  • In a further embodiment the side effects are chosen from Headache or Asthenia. [0025]
  • When the pharmaceutically active agent is anagrelide, the composition may be employed in treating a variety of blood disorders, including, but not limited to, myeloproliferative blood disorders or MBDs, such as, for example, essential thrombocythemia, or ET, chronic myelogenous leukemia, or CML, polycythemia vera, or PV, and agnogenic myeloid metaplasia, or AMM. The composition including anagrelide may be administered to an animal, such as a mammal, including human and non-human primates, in an amount effective to treat such disorders. [0026]
  • The active agent anagrelide may be administered to a patient in an amount of from about 0.01 mg to 15 mg, preferably from about 0.1 mg to about 10 mg, more preferably from about 0.1 mg to about 5 mg and most preferably from about 0.5 mg to about 2 mg. In one treatment regimen, anagrelide may be administered to a patient in an amount of 0.5 mg four times a day, or 1 mg twice a day, for at least one week. When anagrelide is administered as part of a composition in accordance with the present invention, there is a reduction in the number of side effects associated with the administration of anagrelide, or a reduction of the likelihood of side effects associated with the administration of anagrelide. [0027]
  • In accordance with a further aspect of the present invention there is provided a pharmaceutical composition comprising anagrelide as an active agent and characterized in that said composition when administered to a patient produces less of the side effects usually associated with anagrelide. [0028]
  • In one embodiment the side effects are chosen from Headache, Asthenia, Somnolence, Dizziness, Tacchycardia, Nausea, Pain Abdominal, Infect, Vomit, or Palpitations. [0029]
  • In a further embodiment the side effects are chosen from Headache or Asthenia. [0030]
  • The invention now will be described with respect to the following examples; however, the scope of the present invention is not intended to be limited thereby.[0031]
  • EXAMPLE 1
  • Formulations in accordance with the present invention, as well as control formulations, were prepared according to the direct compression described hereinabove. In accordance with such method, guanfacine HCl and other ingredients were sieved through a 40 mesh steel screen. The sieved materials then were charged into a Blendmaster blender (Patterson-Kelley Co.), and blended for 10 minutes with an intensifier bar on for 3 minutes. The blends then are compressed into tablets on a rotary tablet press (Stokes-Merrill Corp., Model 512) using appropriate tooling [0032]
  • The formulations are given in Table 1 below [0033]
    TABLE 1
    PD0052-22A PD0052-25B PD0052-28B PD0052-32B PD0052-32D PD0052-39A
    Ingredient
    1* 2** 1 2 1 2 1 2 1 2 1 2
    Guanfacine  0.57  1.14  0.57  1.14  0.57  1.14  0.57  1.14  0.57  1.14  0.57  1.14
    HCl
    Lactose 37.43 74.86 45.00 90.00 65.00 130.00 
    ProSolv 20.00 40.00 30.00 60.00 29.82 59.64
    Polyox WSR 40.00 80.00 40.00 80.00 40.00 80.00 10.00 20.00
    Ethocel FP 40.00 80.00 39.82 79.64
    Cellulose 50.00 100.00 
    acetate
    Sodium 20.00 40.00
    alginate
    Carrageenan 19.91 39.82
    Carbopol 10.00 20.00
    974P
    Fumaric acid  5.00 10.00
    Eudragit  5.00 10.00
    L100-55
    EDTA  0.50  1.00
    Compritol  9.43 18.86  9.43 18.63  9.43 18.63  9.43 18.63  9.37 18.74
    Stearic acid  2.00  4.00
  • The dissolution data was determined as follows: [0034]
  • A Vankel dissolution tester (VanKel Industries, Edison, N.J.) was used for all dissolution studies. The apparatus was calibrated according to USP23. The dissolution in 0.1N hydrochloric acid (pH 1.2) or pH 6.8 phosphate buffer was tested using the paddle method (USP Apparatus II), employing 500 ml of dissolution medium at a temperature of 37° C. and an agitation rate of 50 rpm. Samples at specific time points were removed and filtered through a 35 μm filter. The filtered samples were kept in screw cap glass test tubes until analysis. An HPLC system comprised of an autosampler and a pump and a UV detector was used for sample analysis. 50 μl of the dissolution samples were injected directly on the HPLC C18 column using a mixture of acetonitrile and acetate buffer (20:80) as the mobile phase. [0035]
  • The dissolution data are given in Table 2 below. [0036]
    TABLE 2
    Dissolution Data for Guanfacine Sustained Release Tablets
    Time PD0052-22A PD0052-25B PD0052-28B PD0052-32B PD0052-32D PD0052-39A
    (hour) 1* 2** 1 2 1 2 1 2 1 2 1 2
    0.5 14.0 ± 0.6  7.0 ± 1.2 13.0 ± 1.5  5.0 ± 0.6  8.4 ± 2.1 10.0 ± 0.6 19.0 ± 1.2 12.0 ± 0.0 31.0 ± 1.2 11.0 ± 1.0 14.0 ± 0.6 10.0 ±
    1.0
    1.0 24.0 ± 1.0 12.0 ± 1.0 27.0 ± 2.0  7.0 ± 1.0 41.0 ± 1.7 20.0 ± 1.0 31.0 ± 2.6 20.0 ± 0.6 48.0 ± 1.2 19.0 ± 0.6 25.0 ± 1.0 18.0 ±
    2.0
    2.0 44.0 ± 0.6 19.0 ± 1.5 48.0 ± 2.5 11.0 ± 0.6 64.0 ± 2.5 36.0 ± 2.5 50.0 ± 4.2 35.0 ± 0.6 80.0 ± 5.6 31.0 ± 1.2 42.0 ± 1.0 31.0 ±
    4.0
    3.0 59.0 ± 0.6 26.0 ± 1.5 63.0 ± 1.7 14.0 ± 0.6 77.0 ± 2.6 49.0 ± 3.6 65.0 ± 6.1 49.0 ± 1.0 96.0 ± 5.0 46.0 ± 0.6 56.0 ± 2.6 46.0 ±
    4.4
    4.0 71.0 ± 6.0 31.0 ± 2.9 74.0 ± 1.5 16.0 ± 0.6 86.0 ± 3.2 59.0 ± 3.2 77.0 ± 5.5 61.0 ± 1.0  104 ± 3.5 56.0 ± 0.6 69.0 ± 3.0 56.0 ±
    5.8
    6.0 90.0 ± 2.0 39.0 ± 2.5 86.0 ± 1.7 19.0 ± 0.0 97.0 ± 3.5 71.0 ± 5.0 99.0 ± 4.4 87.0 ± 2.5  111 ± 4.0 74.0 ± 1.2 90.0 ± 2.6 72.0 ±
    6.2
    8.0 99.0 ± 1.7 46.0 ± 2.5 93.0 ± 2.1 21.0 ± 1.0  108 ± 3.8 80.0 ± 5.5  102 ± 1.2 97.0 ± 1.5  112 ± 4.0 89.0 ± 2.3  102 ± 2.3 83.0 ±
    6.4
    12.00  105.0 ± 61.0 ± 4.7  100.0 ± 25.0 ± 1.0  113 ± 3.6 91.0 ± 6.0  103 ± 2.3 98.0 ± 1.0  113 ± 3.8  107 ± 2.9  112 ± 0.6 96.0 ±
     1.5  1.2 4.2
  • The above results show that the compositions of the present invention have improved dissolution profiles when compared with the control compositions. [0037]
  • EXAMPLE 2
  • Formulations in accordance with the present invention, as well as control formulations, were prepared according to the direct compression method described hereinabove. In accordance with such method, guanfacine HCl and other ingredients were sieved through a 40 mesh steel screen. The sieved materials then were charged into a Blendmaster blender (Patterson-Kelley Co.), and blended for 10 minutes with an intensifier bar on for 3 minutes. The blends then are compressed into tablets on a rotary tablet press (Stokes-Merrill Corp., Model 512) using appropriate tooling [0038]
  • The formulations are given in Table 3 below. [0039]
    TABLE 3
    Weight Percentage of Components in Guanfacine MR Tablets, 1 mg,
    Batch Numbers 2015.00.001, 2016.00.001 and 2018.00.001
    2015.00.001 2016.00.001 2018.00.001
    Component (%) (%) (%)
    Guanfacine HCl, USP 0.57 0.57 0.57
    Hydroxypropryl 10.00 15.00 5.00
    Methylcellulose (Methocel
    K4M Premium CR), USP/NF
    Methacrylic Acid Copolymer 25.00
    (Eudragit L 100-55), USP/NF
    Ammonio Methacrylate 25.00 22.50
    Copolymer (Eudragit RSPO),
    USP/NF
    Silicified Microcrystalline 25.00 20.00 34.43
    Cellulose (Prosolv HD 90)
    Lactose Monohydrate 24.43 24.43 20.00
    Povidone
    Crospovidone Granulated
    Blend (Ludipress)
    Fumaric Acid, USP/NF 5.00 10.00 5.00
    Glyceryl Behenate (Compritol 10.00 5.00 12.50
    888 ATO), USP/NF
    Total 100.00 100.00 100.00
  • EXAMPLE 3
  • The solubility of anagrelide HCl in aqueous solutions in the pH range of 1 to 11.4 at 25° C. was determined. The solubility-pH profile of anagrelide HCl is shown in FIG. 1. Below [0040] pH 3, the solubility increased as the pH decreased which is consistent with formation of a more soluble protonated form. At pH 0.96 the solubility was 236 mcg/mL. Above pH 4, the solubility was independent of pH and remained constant (ca. 1.2 mcg/mL) up to pH 8. Above pH 8, the solubility increased with increasing pH which is due to the ionization of the quinazoline moiety. The solubility at pH 11.4 was 992 mcg/mL.
  • Formulations I through IV were formulated according to the procedure described in Example 1, except that anagrelide HCl has been substituted for guanfacine HCl. [0041]
  • The formulations are given in Table 4 below. [0042]
    TABLE 4
    Formulation I Formulation II Formulation III Formulation IV
    Ingredients mg/Tablet % mg/Tablet % mg/Tablet % mg/Tablet %
    Anagrelide HCl  2.44  1.22  2.44  1.22  2.44  1.22  2.44  1.22
    (2.0 base) (2.0 base) (2.0 base) (2.0 base)
    Polyox WSR 301 30.00 15.00 50.00 25.00
    Prosolv HD 90 60.00 30.00 60.00 30.00 66.00 33.00 80.00 40.00
    Fujicalin SG* 60.00 30.00 30.00 15.00 60.00 30.00 40.00 20.00
    Eudragit L 100-55 20.00 10.00 30.00 15.00 24.00 12.00 20.00 10.00
    Ethocel Std. 30.00 15.00
    100 FP
    Fumaric Acid 10.00  5.00 10.00  5.00
    Compritol 17.56  8.78 17.56  8.78 17.56  8.78 17.56  8.78
    888 ATO
    Polyox WSR N80 40.00 20.00
    Formulation # PD0073-55A PD0073-57A PD0073-64A PD0073-78A
    Total 200.00  100.00  200.00  100.00  200.00  100.00  200.00  100.00 
  • A Vankel dissolution tester (VanKel Industries, Edison, N.J.) was used for all dissolution studies. The apparatus was calibrated according to USP 23. The dissolution in 0.1N hydrochloric acid (pH 1.1) with 0.1% Tween 80 or pH 6.8 phosphate buffer with 0.1% Tween 80 was tested using the paddle method (USP Apparatus II), employing 900 ml of dissolution medium at a temperature of 37° C., and an agitation rate of 100 rpm. Samples at specific time points were removed and filtered through a 70 μm filter. The filtered samples were kept in screw cap glass test tubes until analysis. An HPLC system composed of an autosampler and a pump and a UV detector was used for sample analysis. 20 μl of the dissolution samples were injected directly on the HPLC C18 column using a mixture of acetonitrile and ammonium acetate buffer (36:64) as the mobile phase. [0043]
  • The dissolution data are given in Table 5 below. [0044]
    TABLE 5
    Dissolution Data for Anagrelide Sustained Release Tablets
    PD0073-55A PD0073-57A PD0073-64A PD0073-78A
    Time(hour) 1* 2** 1 2 1 2 1 2
    0.5 N/A  4.0 ± 0.6  6.0 ± 0.0  2.0 ± 0.0 27.0 ± 2.1  5.0 ± 1.0 16.0 ± 0.6 12.0 ± 1.2
    1.0 13.0 ± 0.6  6.0 ± 0.0  9.0 ± 0.6  3.0 ± 0.0 39.0 ± 3.1 11.0 ± 2.9 27.0 ± 1.5 30.0 ± 1.0
    2.0 21.0 ± 0.6 10.0 ± 0.6 15.0 ± 0.6  7.0 ± 0.0 52.0 ± 4.5 31.0 ± 3.2 43.0 ± 3.6 56.0 ± 1.7
    4.0 40.0 ± 2.5 22.0 ± 1.2 30.0 ± 2.3 16.0 ± 0.6 69.0 ± 5.3 58.0 ± 3.5 55.0 ± 4.4 72.0 ± 1.2
    8.0 72.0 ± 5.0 57.0 ± 7.4 57.0 ± 2.0 39.0 ± 1.0 85.0 ± 2.6 73.0 ± 2.6   67 ± 5.5 78.0 ± 0.6
    12.0  95.0 ± 2.9 77.0 ± 5.3 77.0 ± 2.1 62.0 ± 3.6 88.0 ± 1.0 79.0 ± 2.1   83 ± 3.6 82.0 ± 0.0
  • EXAMPLE 4
  • Formulations V, VI, and VII, which are modifications of Formulation IV of Example 2, include the following components as shown in Table 6 below. [0045]
    TABLE 6
    Formulation V Formulation VI Formulation VII
    Component mg/tablet % mg/tablet % mg/tablet %
    Anagrelide HCl, Monohydrate* 0.63 0.315 1.26 0.630 1.88 0.940
    Polyethylene Oxide, 60 Mesh, NF 40.00 20.000 40.00 20.000 40.00 20.000
    (Polyox ™ WSR N80)
    Dibasic Calcium Phosphate, Anhydrous, 39.21 19.605 37.18 18.590 38.56 19.280
    USP
    (Fujicalin SG)
    Silicified High Density Microcrystalline 80.00 40.000 80.00 40.000 80.00 40.000
    Cellulose (Prosolv HD 90), USP
    Methacrylic Acid Copolymer, NF 20.00 10.000 20.00 10.000 20.00 10.000
    (Eudragit L 100-55)
    Glyceryl Behenate, NF 17.56 8.780 17.56 8.780 17.56 8.780
    (Compritol 888 ATO)
    Magnesium Stearate Powder, NF 2.00 1.000 2.00 1.000 2.00 1.00
    (Non-Bovine)
    Green PB-1763 0.60 0.300
    Purple PB-1855 2.00 1.000
    Total 200.0 100.0 200.0 100.0 200.0 100.0
  • Formulations V, VI, and VII were prepared and processed into tablets according to the following procedure: [0046]
  • Blending [0047]
  • 1. Weigh all the ingredients (Prosolv HD90 is divided into 3 portions). [0048]
  • 2. Place the ingredients in the order listed below into the V-blender equipped with an intensifier bar: [0049]
  • a. Prosolv [0050] HD90 portion #1
  • b. Anagrelide HCl Monohydrate [0051]
  • c. Green PB-1763 for Formulation V; Purple PB-1855 for Formulation VI strength; no color for Formulation VII [0052]
  • d. Prosolv [0053] HD90 portion #2
  • 3. Blend for 4 minutes in a V-blender with the intensifier bar off. Turn the intensifier bar on and blend for 2 minutes. Turn the intensifier bar off and blend for 4 minutes. [0054]
  • 4. Pass the blend through a 30-mesh screen using a Comil at the low speed setting. [0055]
  • 5. Pass Prosolv [0056] HD90 portion #3 through the same Comil using the 30-mesh screen and low speed.
  • 6. Place the ingredients into the larger V-blender equipped with an intensifier bar in the following order: [0057]
  • a. Milled Prosolv HD90 from [0058] Step 5
  • b. Polyox WSR N80, 60 mesh [0059]
  • c. Milled blend from [0060] Step 4
  • d. Eudragit L100-55 [0061]
  • e. Fujicalin SG [0062]
  • 7. Blend these ingredients for 4 minutes with intensifier bar off. Turn the intensifier bar on and blend for 2 minutes. Turn the intensifier bar off, add Compritol 888 ATO and blend for 4 minutes. [0063]
  • 8. Discharge this blend from the V-blender into a suitable container. [0064]
  • 9. Pass Magnesium Stearate through a 30-mesh screen and collect it in a polyethylene bag. [0065]
  • 10. Pass the blend from [0066] step 8 through a 30-mesh screen using a Comil at the low speed setting and collect it in a polyethylene bag.
  • 11. Transfer the milled blend from [0067] step 10 and the Magnesium Stearate from step 9 into the V-blender used in step 7 and mix for 5 minutes with the intensifier bar off.
  • 12. Discharge the blend from [0068] step 11 into a polyethylene bag.
  • Tableting [0069]
  • 1. Load the blend into the tablet press hopper. [0070]
  • 2. Adjust the tablet weight to 200 mg and the appropriate tablet hardness. [0071]
  • 3. Compress the blend into tablets using caplet-shaped tooling. [0072]
  • 4. Take tablet samples as required by departmental SOPs to ensure product quality and to complete any process protocols of the tableting process. [0073]
  • 5. Run tablets through an appropriate deduster. [0074]
  • 6. Collect compressed tablets in a suitable container double lined with clean polyethylene bags. [0075]
  • EXAMPLE 5
  • [0076] Formulations 1, 2, and 3, were prepared, which had the following components in the following amounts, as shown in Table 7 below.
    TABLE 7
    Amount, wt %
    Formulation Formulation Formulation
    Component
    1 2 3
    Anagrelide HCl, Monohydrate 0.61 0.61 0.61
    Polyethylene Oxide 15.00 25.00
    (Polyox ™ WSR 301)
    Polyethylene Oxide, 60 Mesh, 20.00
    NF (Polyox ™ WSR N80)
    Dibasic Calcium Phosphate, 30.61 20.61 30.61
    Anhydrous, USP
    (Fujicalin SG)
    Silicified High Density 30.00 40.00 15.00
    Microcrystalline Cellulose
    (Prosolv HD 90), USP
    Methacrylic Acid Copolymer 10.00 10.00 15.00
    (Eudragit L 100-55)
    Fumaric Acid 5.00 5.00
    Glyceryl Behenate, NF 8.78 8.78 8.78
    (Compritol 888 ATO)
    Total 100.0 100.0 100.0
  • The purpose of this example was to assess the bioavailability of three anagrelide HCl extended release tablet [0077] formulationsFormulation 1Formulation 2Formulation 3, compared to an immediate release anagrelide HCl formulation (Agrylin®, Lot No. RPA 0002A), following a 1 mg dose, and to determine the safety and tolerability of the extended release formulations in healthy volunteers.
  • The extent of absorption of each drug (AUC[0078] o-t) the maximum concentration of drug in plasma (Cmax), and the time of the maximum concentration (Tmax) were evaluated.
  • The mean plasma concentrations for anagrelide following administration of a single 1 mg dose of Agrylin®, or the anagrelide HCl [0079] extended release Formulations 1, 2, or 3, are given in FIG. 2.
  • The corresponding pharmacokinetic parameters for each formulation are given in Table 8 below. [0080]
    TABLE 8
    Mean Pharmacokinetic Parameters for Anagrelide
    Twidth
    AUC0-inf AUC0-t Cmax Tmax ♭Cmax
    Treatment (ng · hr/mL) (ng · hr/mL) (ng/mL) (hr) (hr)
    Formulation 1 9.24* 8.47* 1.15* 3.41* 5.06
    Formulation 2 10.32* 9.10* 1.01* 3.17* 5.99
    Formulation 3 9.41* 8.48* 1.17* 3.46* 4.30
    Agrylin ® 14.89 14.46 5.67 1.25 2.17
    Bioequivalence
    Formulation 1: 0.61 0.58 0.21
    Ratio of
    test-to-ref.
    90% CI 0.49-0.76 0.46-0.73 0.17-0.27
    Formulation 2: 0.59 0.53 0.17
    Ratio of
    test-to-ref.
    90% CI 0.47-0.74 0.42-0.67 0.14-0.22
    Formulation 3: 0.66 0.64 0.25
    Ratio of
    test-to-ref.
    90% CI 0.52 0.50-0.81 0.20-0.32
  • All three experimental formulations exhibited extended release characteristics for drug delivery. The extent of absorption of anagrelide from the experimental formulations relative to immediate-release Agrylin® (ratio of test-to-reference) was 58%, 53% and 64% for the [0081] Formulations 1, 2 and 3, respectively.
  • A measure of the extent of delay in release of active pharmaceutical ingredient of the experimental formulations was the time to reach maximum concentration (T[0082] max) values observed for anagrelide. The Tmax values were approximately 2 hours later than that observed for Agrylin®, demonstrating about a 2.6-fold delay in time to reach Cmax for the three extended release formulations compared with the immediate-release Agrylin®. Furthermore, the length of time at which the anagrelide plasma concentration remained above ½Cmax (Twidth ½Cmax) was approximately two- to three-fold greater for the extended release formulations than the immediate release formulation, demonstrating good extended release characteristics.
  • No serious adverse events were reported. One subject discontinued due to an adverse event (head cold) considered not related to study drug. There were a total of 46 adverse events (AEs) experienced by eleven (11) subjects. The most frequently reported events (>5%), included asthenia, headache, somnolence, and dizziness, and were not unexpected. These events have been reported frequently by the target patient population at large receiving Agrylin® for the treatment of thrombocythemia secondary to all myeloproliferative disorders. Treatment emergent AEs are summarized in Table 9. [0083]
    TABLE 9
    Treatment Emergent AEs
    Preferred Term (Costart) Count % (n = 12)
    Asthenia 12  26.1
    Headache 9 19.6
    Somnolence 6 13.0
    Dizziness 5 10.9
    Tachycardia 2 4.3
    Infection 2 4.3
    Nausea 2 4.3
    Vomit 2 4.3
    Pain Abd 1 2.2
    Palpitations 1 2.2
    Pain 1 2.2
    Hem 1 2.2
    Voice alteration 1 2.2
    Thirst 1 2.2
    Total 46  100.0
  • The data would indicate that adverse events (AEs) observed in subjects following dosage with the extended release formulation were not as prevalent as AEs observed following the immediate release formulation (Agrylin®). More than 50% of the reported AEs were observed following Agrylin® administration. The number of adverse events following administration of the new extended release formulations were 8/46 (17%) for [0084] Formulation 1, 9/46 (20%) for Formulation 2, and 4/46 (9%) for Formulation 3 compared to 25/46 (54%) for the marketed Agrylin®. The incidence of subjects reporting adverse events for the new extended-release formulations (4/12 (33%), 6/12 (50%), and 2/12 (17%) for Formulations 1, 2, and 3, respectively) also were substantially lower than the incidence observed in the Agrylin® group (10/12 (83%)). The number and percentage of subjects reporting adverse events are presented in Table 10.
    TABLE 10
    Treatment Emergent Adverse Events per Treatment Group
    Preferred No. %
    Term Subjects Subjects No. AEs
    Drug Treatment (Costart) Reporting Reporting Reported
    Formulation 1 Asthenia 3 25.0 3
    (n = 12) Nausea 1 8.3 1
    Pain 1 8.3 1
    Somnolence 1 8.3 1
    Thirst 1 8.3 1
    Vomit 1 8.3 1
    Formulation 2 Asthenia 3 25.0 3
    (n = 12) Dizziness 2 16.7 2
    Headache 2 16.7 2
    Somnolence 1 8.3 1
    Hem 1 8.3 1
    Formulation 3 Asthenia 1 9.3 1
    (n = 11) Headache 1 9.3 1
    Infect 1 9.3 1
    Voice 1 9.3 1
    alteration
    Agrylin ® Headache 6 50.0 6
    (n = 12) Asthenia 5 41.7 5
    Somnolence 3 25.0 4
    Dizziness 3 25.0 3
    Tacchycardia 2 16.7 2
    Nausea 1 8.3 1
    Pain 1 8.3 1
    Abdominal
    Infect 1 8.3 1
    Vomit 1 8.3 1
    Palpitations 1 8.3 1
    Total (n = 12) 46 
  • With respect to clinical laboratory and physical examination findings, statistically significant (p<0.01) increases in pulse compared with baseline were observed with Agrylin® at 2, 4, and 24 hours post dose. Significant increases were observed at 24 hours post dose for [0085] Formulations 1 and 3. Only Agrylin® showed a statistically significant changed from baseline for blood pressure (i.e. at 24 hours post dose for diastolic blood pressure).
  • It is to be understood, however, that the scope of the present invention is not to be limited to the specific embodiments described above. The invention may be practiced other than as particularly described and still be within the scope of the accompanying claims. [0086]

Claims (73)

What is claimed is:
1. A pharmaceutical composition, comprising:
(a) at least one pharmaceutically active agent that is pH dependent:
(b) at least one non-pH dependent sustained release agent; and
(c) at least one pH dependent agent that increases the rate of release of said at least one pharmaceutically active agent from the tablet at a pH in excess of 5.5.
2. The composition of claim 1 wherein said at least one pH dependent agent is at least one polymer that swells at a pH in excess of 5.5.
3. The composition of claim 1 wherein said at least one pH dependent agent is at least one enteric agent.
4. The composition of claim 1 wherein said at least one pH dependent agent is at least one agent that increases the solubility of said at least one pharmaceutically active agent at a pH of greater than 5.5.
5. The composition of claim 1 wherein said at least one pharmaceutically active agent is selected from the group consisting of guanfacine, anagrelide, guanethidine monosulfate, quanadrel sulfate, resirpine, propanolol, metoprolol, atenolol, timolol, erythromycin, clonidine, chlorpheniramine, bromopheniramine, diltiazem, and scopolamine.
6. The composition of claim 5 wherein said at least one pharmaceutically active agent guanfacine.
7. The composition of claim 5 wherein said at least one pharmaceutically active agent guanfacine hydrochloride.
8. The composition of claim 5 wherein said at least one pharmaceutically active agent is anagrelide.
9. The composition of claim 5 wherein said at least one pharmaceutically active agent is anagrelide hydrochloride.
10. The composition of claim 1 wherein said non-pH dependent sustained release agent is selected from the group consisting of ethylcellulose, cellulose acetate, vinyl acetate/vinyl chloride copolymers, acrylate/methacrylate copolymers, polyethylene oxide, hydroxypropyl methylcellulose, carageenan, alginic acid and salts thereof, hydroxyethyl cellulose, hydroxypropyl cellulose, karaya gum, acacia gum, trgacanth gum, locust bean gum, guar gum, sodium carboxymethyl cellulose, methyl cellulose, beeswax, carnauba wax, cetyl alcohol, hydrogenated vegetable oils, and stearyl alcohol.
11. The composition of claim 2 wherein said at least one polymer that swells at a pH in excess of 5.5 is selected from the group consisting of acrylic acid copolymers, sodium alginate, carrageenan, alginic acid, pectin, and sodium carboxymethyl cellulose.
12. The composition of claim 3 wherein said at least one enteric agent is selected from the group consisting of cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, polvinyl acetate phthalate, methacrylic acid copolymers, cellulose acetate trimellitate, hydroxypropyl methylcellulose acetate, succinate, shellac, and zein.
13. The composition of claim 4 wherein said at least one agent that increase the solubility of said at least one pharmaceutically active agent at a pH greater than 5.5 is at least one organic acid.
14. The composition of claim 13 wherein said at least one organic acid is selected from the group consisting of citric acid, fumaric acid, tartaric acid, adipic acid, glucono delta-lactone, and malic acid.
15. The composition of claim I wherein said pH-dependent agent that increases the rate of release of the at least one pharmaceutically active agent from the tablet at a pH in excess of 5.5 is an agent that maintains an acidic microenvironment in the composition.
16. The composition of claim 14 wherein said organic acid is fumaric acid.
17. The composition of claim 1 and further comprising a binding agent.
18. The composition of claim 17 wherein said binding agent is selected from the group consisting of polyvinyl pyrrolidone, starch, methylcellulose, hydroxypropyl methylcellulose, carboxymethyl cellulose, sucrose solution, dextrose solution, acacia, tragacanth, and locust bean gum.
19. The composition of claim 18 wherein said binder is hydroxypropyl methylcellulose.
20. The composition of claim 1 wherein said pharmaceutically active agent is present in the composition in an amount of from about 0.1 wt. % to about 70 wt. %.
21. The composition of claim 20 wherein said pharmaceutically active agent is present in the composition in an amount of from about 1 wt. % to about 40 wt. %.
22. The composition of claim 1 wherein said non-pH-dependent sustained release agent is present in the composition in an amount of from about 5 wt. % to about 50 wt. %.
23. The composition of claim 22 wherein said non-pH-dependent sustained release agent is present in the composition in an amount of from about 10 wt. % to about 30 wt. %.
24. The composition of claim 1 wherein said at least one pH-dependent agent is present in the composition in an amount of from about 0.5 wt. % to about 40 wt. %.
25. The composition of claim 24 wherein said at least one pH-dependent agent is present in the composition in an amount of from about 1 wt. % to about 20 wt. %.
26. The composition of claim 10 wherein said non-pH-dependent sustained release agent is ethyl cellulose.
27. The composition of claim 10 wherein said non-pH-dependent sustained release agent is hydroxypropyl methylcellulose.
28. The composition of claim 10 wherein said non-pH-dependent sustained release agent is an acrylate/methacrylate copolymer.
29. The composition of claim 10 wherein said non-pH-dependent sustained release agent is polyethylene oxide.
30. The composition of claim 11 wherein said at least one polymer that swells at a pH in excess of 5.5 is sodium alginate.
31. The composition of claim 12 wherein said at least one enteric agent is a methacrylic acid copolymer.
32. The composition of claim 1 wherein said composition is in the form of a tablet.
33. The composition of claim 6 or 7 wherein said non-pH-dependent sustained release agent is selected from the group consisting of ethylcellulose, cellulose acetate, vinyl acetate/vinyl chloride copolymers, acrylate/methacrylate copolymers, polyethylene oxide, hydroxypropyl methylcellulose, carrageenan, alginic acid and salts thereof, hydroxyethyl cellulose, hydroxypropyl cellulose, karaya gum, acacia gum, tragacanth gum, locust bean gum, guar gum, sodium carboxymethyl cellulose, methyl cellulose, beeswax, carnauba wax, cetyl alcohol, hydrogenated vegetable oils, and stearyl alcohol.
34. The composition of claim 6 or 7 wherein said at least one pH-dependent agent is at least one polymer that swells at a pH in excess of 5.5.
35. The composition of claim 34 wherein said at least one polymer that swells at a pH in excess of 5.5 is selected from the group consisting of acrylic acid copolymers, sodium alginate, carrageenan, alginic acid, pectin, and sodium carboxymethyl cellulose.
36. The composition of claim 6 or 7 wherein said at least one pH-dependent agent is at least one enteric agent.
37. The composition of claim 36 wherein said at least one enteric agent is selected from the group consisting of cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, polyvinyl acetate phthalate, methacrylic acid copolymers, cellulose acetate trimellitate, hydroxypropyl methylcellulose acetate, succinate, shellac, and zein.
38. The composition of claim 8 or 9 wherein said non-pH-dependent sustained release agent is selected from the group consisting of ethylcellulose, cellulose acetate, vinyl acetate/vinyl chloride copolymers, acrylate/methacrylate copolymers, polyethylene oxide, hydroxypropyl methylcellulose, carageenan, alginic acid and salts thereof, hydroxyethyl cellulose, hydroxypropyl cellulose, karaya gum, acacia gum, tragacanth gum, locust bean gum, guar gum, sodium carboxymethyl cellulose, methylcellulose, beeswax, carnauba wax, cetyl alcohol, hydrogenated vegetable oils, and stearyl alcohol.
39. The composition of claim 38 wherein said non-pH-dependent sustained release agent is polyethylene oxide.
40. The composition of claim 8 or 9 wherein said at least one pH-dependent agent is at least one enteric agent.
41. The composition of claim 40 wherein said at least one enteric agent is selected from the group consisting of cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, polyvinyl acetate phthalate, methacrylic acid copolymers, cellulose acetate trimellitate, hydroxypropyl methylcellulose acetate, succinate, shellac, and zein.
42. The composition of claim 41 wherein said at least one enteric agent is a methacrylic acid copolymer.
43. The composition of claim 8 or 9 and further comprising a bulking agent.
44. The composition of claim 43 wherein said bulking agent is dibasic calcium phosphate.
45. The composition of claim 43 wherein said bulking agent is microcrystalline cellulose.
46. The composition of claim 8 or 9 and further comprising a lubricant.
47. The composition of claim 46 wherein said lubricant is glyceryl behenate.
48. The composition of claim 46 wherein said lubricant is magnesium stearate.
49. A pharmaceutical composition, comprising:
(a) anagrelide;
(b) polyethylene oxide;
(c) dibasic calcium phosphate;
(d) microcrystalline cellulose;
(e) a methacrylic acid copolymer;
(f) glyceryl behenate; and
(g) magnesium stearate.
50. A pharmaceutical composition, comprising:
(h) Anagrelide hydrochloride;
(i) polyethylene oxide;
(j) dibasic calcium phosphate;
(k) microcrystalline cellulose;
(l) a methacrylic acid copolymer;
(m) glyceryl behenate; and
(n) magnesium stearate.
51. A method of treating a myeloproliferative blood disorder in a patient, comprising: administering to said patient the composition of anyone of claims 8 to 50 in an amount effective to treat said myeloproliferative blood disorder in said patient.
52. The method of claim 51 wherein said myeloproliferative blood disorder is essential thrombocythemia.
53. The method of claim 51 wherein said myeloproliferative blood disorder is chronic myelogenous leukemia.
54. The method of claim 51 wherein said myeloproliferative blood disorder is polycythemia vera.
55. The method of claim 51 wherein said myeloproliferative blood disorder is agnogenic myeloid metaplasia.
56. The method of claim 51 wherein the amount of the active ingredient anagrelide is about 0.01 mg to about 15 mg.
57. The method of claim 51 wherein the amount of the active ingredient anagrelide is about 0.1 mg to about 10 mg.
58. The method of claim 51 wherein the amount of the active ingredient anagrelide is about 0.1 mg to about 5 mg.
59. The method of claim 51 wherein the amount of the active ingredient anagrelide is about 0.5mg to about 2 mg.
60. A pharmaceutical composition comprising anagrelide as an active agent and characterized in that said composition when administered to a patient produces less of the side effects usually associated with anagrelide.
61. The pharmaceutical composition of claim 60 wherein said side effects are chosen from Headache, Asthenia, Somnolence, Dizziness, Tacchycardia, Nausea, Pain Abdominal, Vomit, Infect or Palpitations.
62. The pharmaceutical composition of claim 61 wherein said side effects are chosen from Headache and Asthenia.
63. The pharmaceutical composition of claim 61 wherein said side effect is Headache.
64. The pharmaceutical composition of claim 61 wherein said side effect is Asthenia.
65. A method of reducing the likelihood of side effects associated with the administration of anagrelide, comprising administering to a patient a therapeutically effective amount of a composition as defined in anyone of claims 8 to 50.
66. The method of claim 65 wherein said side effects are chosen from Headache, Asthenia, Somnolence, Dizziness, Tacchycardia, Nausea, Pain Abdominal, Vomit, Infect, or Palpitations.
67. The method of claim 65 wherein said side effects are chosen from Headache and Asthenia.
68. The method of claim 65 wherein said side effect is Headache.
69. The method of claim 65 wherein said side effect is Asthenia
70. A pharmaceutical composition, comprising:
(a) guanfacine;
(b) Hydroxypropyl Methylcellulose
(c) Ammonio Methacrylate Copolymer
(d) microcrystalline cellulose;
(e) a methacrylic acid copolymer;
(f) glyceryl behenate; and
(g) Fumaric Acid,
(h) Lactose Monohydrate
(i) Povidone; and
(j) Crospovidone Granulated Blend.
71. A pharmaceutical composition comprising:
(a) Guanfacine hydrochloride;
(b) Hydroxypropyl Methylcellulose
(c) Ammonio Methacrylate Copolymer
(d) microcrystalline cellulose;
(e) a methacrylic acid copolymer;
(f) glyceryl behenate; and
(g) Fumaric Acid,
(h) Lactose Monohydrate
(i) Povidone; and
(j) Crospovidone Granulated Blend.
72. A method of treating an attention deficit disorder or attention deficit with hyperactivity disorder in a patient, comprising administering to said patient the composition of claim 6 or 7 in an amount effective to treat said attention deficit disorder or attention deficit with hyperactivity disorder in said patient.
73. A method of reducing the likelihood of side effects associated with the administration of guanfacine, comprising administering to a patient a therapeutically effective amount of the composition of claim 6 or 7
US10/451,271 2000-12-20 2001-12-20 Sustained release pharmaceutical dosage forms with minimized ph dependent dissolution profiles Abandoned US20040062800A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/451,271 US20040062800A1 (en) 2000-12-20 2001-12-20 Sustained release pharmaceutical dosage forms with minimized ph dependent dissolution profiles

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US09741548 2000-12-20
US09/741,548 US6287599B1 (en) 2000-12-20 2000-12-20 Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
PCT/US2001/050773 WO2002058676A1 (en) 2000-12-20 2001-12-20 Sustained release pharmaceutical dosage forms with minimized ph dependent dissolution profiles
US10/451,271 US20040062800A1 (en) 2000-12-20 2001-12-20 Sustained release pharmaceutical dosage forms with minimized ph dependent dissolution profiles

Publications (1)

Publication Number Publication Date
US20040062800A1 true US20040062800A1 (en) 2004-04-01

Family

ID=24981155

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/741,548 Expired - Lifetime US6287599B1 (en) 2000-12-20 2000-12-20 Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
US10/451,271 Abandoned US20040062800A1 (en) 2000-12-20 2001-12-20 Sustained release pharmaceutical dosage forms with minimized ph dependent dissolution profiles

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/741,548 Expired - Lifetime US6287599B1 (en) 2000-12-20 2000-12-20 Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles

Country Status (10)

Country Link
US (2) US6287599B1 (en)
EP (1) EP1351668B1 (en)
JP (1) JP4340840B2 (en)
AU (1) AU2002249881B2 (en)
CA (1) CA2432178C (en)
CY (1) CY1116023T1 (en)
DK (1) DK1351668T3 (en)
ES (1) ES2527854T3 (en)
PT (1) PT1351668E (en)
WO (1) WO2002058676A1 (en)

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040087486A1 (en) * 1999-09-21 2004-05-06 Hanson Stephen R. Methods and compositions for treating platelet-related disorders
US20060160852A1 (en) * 2004-12-27 2006-07-20 Eisai Co. Ltd. Composition containing anti-dementia drug
US20060159753A1 (en) * 2004-12-27 2006-07-20 Eisai Co. Ltd. Matrix type sustained-release preparation containing basic drug or salt thereof
US20060246003A1 (en) * 2004-12-27 2006-11-02 Eisai Co. Ltd. Composition containing anti-dementia drug
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
WO2007054976A2 (en) * 2005-11-08 2007-05-18 Panacea Biotec Ltd. Lipid based controlled release pharmaceutical composition
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
US20080213368A1 (en) * 2004-12-27 2008-09-04 Eisai R & D Management Co., Ltd. Method for Stabilizing Anti-Dementia Drug
US20090023778A1 (en) * 2005-04-28 2009-01-22 Eisai R&D Management Co., Ltd. Composition Containing Anti-Dementia Drug
US20090087490A1 (en) * 2007-06-08 2009-04-02 Addrenex Pharmaceuticals, Inc. Extended release formulation and method of treating adrenergic dysregulation
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US20090324710A1 (en) * 2008-06-16 2009-12-31 Glidden Paul F Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
AT10562U3 (en) * 2008-12-05 2010-01-15 Aop Orphan Pharmaceuticals Ag A NEW COMPOSITION FOR TREATING AN ESSENCIAL THROMBOCYTEMIA
US20100172991A1 (en) * 2007-06-08 2010-07-08 Henry Joseph Horacek Extended Release Formulation and Methods of Treating Adrenergic Dysregulation
WO2011085466A1 (en) 2010-01-18 2011-07-21 Medizone International Inc. Bio-terrorism counteraction using ozone and hydrogen peroxide
WO2011117391A3 (en) * 2010-03-25 2012-01-19 Aop Orphan Pharmaceuticals Ag Novel composition for treatment of essential thrombocythemia
US8906420B2 (en) 2009-01-09 2014-12-09 Forward Pharma A/S Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
US9011912B2 (en) 2010-10-07 2015-04-21 Abon Pharmaceuticals, Llc Extended-release oral dosage forms for poorly soluble amine drugs
WO2017182852A1 (en) * 2016-04-20 2017-10-26 Sun Pharmaceutical Industries Limited Extended release liquid compositions of guanfacine
US9962345B2 (en) 2014-05-01 2018-05-08 Sun Pharmaceutical Industries Limited Oral liquid compositions of guanfacine
US9962336B2 (en) 2014-05-01 2018-05-08 Sun Pharmaceutical Industries Limited Extended release suspension compositions
US10238803B2 (en) 2016-05-02 2019-03-26 Sun Pharmaceutical Industries Limited Drug delivery device for pharmaceutical compositions
US10258583B2 (en) 2014-05-01 2019-04-16 Sun Pharmaceutical Industries Limited Extended release liquid compositions of guanfacine
US10285908B2 (en) 2014-07-30 2019-05-14 Sun Pharmaceutical Industries Ltd Dual-chamber pack
US10369078B2 (en) 2016-05-02 2019-08-06 Sun Pharmaceutical Industries Limited Dual-chamber pack for pharmaceutical compositions
US11504345B2 (en) 2014-05-01 2022-11-22 Sun Pharmaceutical Industries Limited Extended release liquid compositions of metformin

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
AR035216A1 (en) 2000-12-01 2004-05-05 Astrazeneca Ab MANDELIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE DERIVATIVES, USE OF THESE DERIVATIVES FOR THE MANUFACTURE OF MEDICINES, TREATMENT METHODS, PROCESSES FOR THE PREPARATION OF THESE DERIVATIVES, AND INTERMEDIARY COMPOUNDS
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
AR034517A1 (en) 2001-06-21 2004-02-25 Astrazeneca Ab PHARMACEUTICAL FORMULATION
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
WO2003039530A1 (en) * 2001-11-07 2003-05-15 Synthon B.V. Tamsulosin tablets
KR101016619B1 (en) * 2001-11-13 2011-02-23 아스텔라스세이야쿠 가부시키가이샤 Soluble drug extended release system
US6811794B2 (en) * 2001-12-20 2004-11-02 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
KR100540035B1 (en) * 2002-02-01 2005-12-29 주식회사 태평양 Multi-stage oral drug controlled-release system
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
KR101002374B1 (en) * 2002-02-26 2010-12-17 아스트라제네카 아베 Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
AU2003230805A1 (en) * 2002-04-05 2003-10-27 Penwest Pharmaceuticals Co. Sustained release metoprolol formulations
SE0201661D0 (en) * 2002-05-31 2002-05-31 Astrazeneca Ab New salts
WO2003105810A1 (en) * 2002-06-14 2003-12-24 Andrx Corporation Pharmaceutical compositions for drugs having ph-dependentsolubility
US8637512B2 (en) * 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
BR0315731A (en) * 2002-10-30 2005-09-06 Pharmacia Corp Extended-Release Oral Tablets and Methods for Manufacturing and Using Them
US7018658B2 (en) * 2002-11-14 2006-03-28 Synthon Bv Pharmaceutical pellets comprising tamsulosin
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
ATE339192T1 (en) * 2003-05-14 2006-10-15 Eurand Pharmaceuticals Ltd CONTROLLED DRUG RELEASE COMPOSITION WITH IN VIVO MECHANICAL STRESS RESISTANCE
US7781424B2 (en) * 2003-05-27 2010-08-24 Astrazeneca Ab Modified release pharmaceutical formulation
US7314640B2 (en) * 2003-07-11 2008-01-01 Mongkol Sriwongjanya Formulation and process for drug loaded cores
GB0317663D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Pharmaceutical composition
US7198653B2 (en) 2003-07-31 2007-04-03 Delavau Llc Calcium carbonate granulation
US20050106253A1 (en) * 2003-11-13 2005-05-19 Platteeuw Johannes J. Pharmaceutical pellets comprising tamsulosin
CN101005830B (en) * 2004-08-13 2010-09-29 贝林格尔·英格海姆国际有限公司 Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
ES2409347T3 (en) 2004-10-21 2013-06-26 Aptalis Pharmatech, Inc. Pharmaceutical compositions of masked flavor with gastro-soluble porogenic agents
US8128952B2 (en) * 2005-01-12 2012-03-06 Clemson University Research Foundation Ligand-mediated controlled drug delivery
JP2008530131A (en) * 2005-02-15 2008-08-07 ジャズ、ファーマシューティカルズ、インコーポレイテッド Dosage forms and methods for sustained release of substituted pyrazine compounds
US20060204575A1 (en) * 2005-03-11 2006-09-14 Hengsheng Feng Amphetamine formulations
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
EP1898886B1 (en) 2005-07-01 2019-09-04 Rubicon Research Pvt Ltd. Novel sustained release dosage form
DK1909766T3 (en) * 2005-07-28 2016-04-04 Shire Llc PHARMACEUTICAL FORMULATIONS / FORMATIONS OF guanfacine SUITABLE FOR DAILY ADMINISTRATION IN SINGLE DOSE FORM
US8778395B2 (en) * 2005-08-11 2014-07-15 Andrx Labs, Llc Diltiazem controlled release formulation and method of manufacture
BRPI0615135A2 (en) * 2005-08-26 2016-09-13 Bpsi Holdings Inc drug compositions containing controlled release hypromellose matrices
DK1931346T3 (en) 2005-09-09 2012-10-22 Angelini Labopharm Llc Trazodone composition for once daily administration
WO2007035874A1 (en) * 2005-09-21 2007-03-29 Bristol-Myers Squibb Company Oral administration of n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-1,3-thiazole-5-carboxamide and salts thereof
US20070092573A1 (en) * 2005-10-24 2007-04-26 Laxminarayan Joshi Stabilized extended release pharmaceutical compositions comprising a beta-adrenoreceptor antagonist
US20070238942A1 (en) * 2006-04-10 2007-10-11 Esophamet Corp. Apparatus and method for detecting gastroesophageal reflux disease (gerd)
MX2008013675A (en) 2006-04-26 2009-03-06 Supernus Pharmaceuticals Inc Controlled released preparations of oxcarbazepine having sigmoidal release profile.
KR100780479B1 (en) 2006-05-08 2007-11-28 윈셋파마 주식회사 Oral drug comprising Ibudilast and manufacturing method
WO2007131804A1 (en) 2006-05-17 2007-11-22 Synthon B.V. Tablet composition with a prolonged release of tamsulosin
US20070281011A1 (en) * 2006-05-30 2007-12-06 Elan Pharma International Ltd. Nanoparticulate posaconazole formulations
US9138414B1 (en) 2006-09-15 2015-09-22 Delavau Llc Calcium supplement having enhanced absorption
TW200827336A (en) 2006-12-06 2008-07-01 Astrazeneca Ab New crystalline forms
US20100081672A1 (en) * 2006-12-07 2010-04-01 Schering Corporation Ph sensitive matrix formulation
TW200900033A (en) * 2007-06-21 2009-01-01 Wen-Qing Li Automatic brewing machine
US20090022789A1 (en) * 2007-07-18 2009-01-22 Supernus Pharmaceuticals, Inc. Enhanced formulations of lamotrigine
US20090061000A1 (en) * 2007-08-31 2009-03-05 Astrazeneca Ab Pharmaceutical formulation use 030
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
ES2402342T3 (en) 2008-08-01 2013-04-30 Krka, Tovarna Zdravil, D.D., Novo Mesto Quetiapine Composition
US20100159001A1 (en) 2008-12-19 2010-06-24 Cardinal John R Extended-Release Pharmaceutical Formulations
US8465770B2 (en) * 2008-12-24 2013-06-18 Synthon Bv Low dose controlled release tablet
CN102438617A (en) 2009-03-27 2012-05-02 杏林制药株式会社 Matrix-type sustained release preparation containing basic additive
EP2506836B1 (en) 2009-12-02 2018-02-14 Adare Pharmaceuticals S.R.L. Fexofenadine microcapsules and compositions containing them
US20110217373A1 (en) * 2010-01-29 2011-09-08 Kumaravel Vivek Extended release pharmaceutical compositions of guanfacine hydrochloride
EP2540294B1 (en) 2010-02-22 2016-08-03 Daiichi Sankyo Company, Limited Sustained-release solid preparation for oral use
JP5749247B2 (en) 2010-02-22 2015-07-15 第一三共株式会社 Oral sustained-release solid preparation
EP2366378A1 (en) 2010-03-01 2011-09-21 Dexcel Pharma Technologies Ltd. Sustained-release donepezil formulations
JP2013526601A (en) * 2010-05-24 2013-06-24 ルピン・リミテッド Sustained release formulation of pramipexole
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US8927010B2 (en) 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
MX2021000431A (en) 2011-03-23 2022-10-28 Ironshore Pharmaceuticals & Dev Inc Methods and compositions for treatment of attention deficit disorder.
WO2013147135A1 (en) * 2012-03-30 2013-10-03 アステラス製薬株式会社 Controlled-release pharmaceutical composition
ES2706994T3 (en) 2012-09-03 2019-04-02 Daiichi Sankyo Co Ltd Orally extended-release pharmaceutical composition containing hydromorphone hydrochloride
AU2013318182C1 (en) 2012-09-18 2022-01-20 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
US9550780B2 (en) 2012-09-18 2017-01-24 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
US20160022591A1 (en) * 2013-03-15 2016-01-28 Mylan Inc. Extended release pharmaceutical solid dosage formulations
US20140309270A1 (en) 2013-04-11 2014-10-16 Richard Louis Price Diagnosis and treatment of a form of autistic spectrum disorder
US20170348417A1 (en) 2013-04-11 2017-12-07 Richard Louis Price Treatment of attention deficit disorders and associated symptoms
US9603812B2 (en) 2013-04-11 2017-03-28 Richard Louis Price Treatment of autistic spectrum disorder
US10098848B2 (en) 2013-04-11 2018-10-16 Richard Louis Price Inositol-containing comestible units and methods of treatment using the same
US9211284B2 (en) 2013-04-11 2015-12-15 Richard Louis Price Diagnosis and treatment of P.R.I.C.E. syndrome
EP2796133A1 (en) 2013-04-26 2014-10-29 Salmon Pharma GmbH Sustained release guanfacine HCl formulation
EP3076970A4 (en) 2013-12-03 2017-07-26 Auspex Pharmaceuticals, Inc. Methods of manufacturing benzoquinoline compounds
CN103784413A (en) * 2014-02-27 2014-05-14 中国药科大学 Atenolol pH independent sustained-release tablets and preparation method thereof
PL2915526T3 (en) 2014-03-07 2021-12-20 Galenicum Health S.L.U. Pharmaceutical compositions comprising anagrelide
KR102335744B1 (en) 2015-03-06 2021-12-07 오스펙스 파마슈티칼스, 인코포레이티드 Methods for treating abnormal involuntary movement disorders
KR20200118507A (en) 2016-02-29 2020-10-15 에프. 호프만-라 로슈 아게 Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase
KR102078462B1 (en) * 2018-07-24 2020-02-17 주식회사 디네이쳐 Composition for improving vagina environment and improving agent having the same
PL3976000T3 (en) * 2019-04-05 2023-12-04 Gedea Biotech Ab Vaginal tablet formulation
JP7149449B2 (en) * 2020-07-02 2022-10-06 ARTham Therapeutics株式会社 Oral pharmaceutical composition and manufacturing method thereof
EP4292587A1 (en) 2022-06-15 2023-12-20 Sawai Pharmaceutical Co., Ltd. Guanfacine hydrochloride containing pharmaceutical preparation

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4404226A (en) * 1981-07-09 1983-09-13 Sandoz Ltd. Use of guanfacine in treating schizophrenia
US4968508A (en) * 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
US5102668A (en) * 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
US5246714A (en) * 1985-10-11 1993-09-21 Aktiebolaget Hassle Drug preparation
US5378474A (en) * 1989-01-06 1995-01-03 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5605911A (en) * 1995-01-31 1997-02-25 Washington University Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH)
US5854290A (en) * 1995-09-21 1998-12-29 Amy F. T. Arnsten Use of guanfacine in the treatment of behavioral disorders
US6245351B1 (en) * 1996-03-07 2001-06-12 Takeda Chemical Industries, Ltd. Controlled-release composition
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
US6811794B2 (en) * 2001-12-20 2004-11-02 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07116044B2 (en) * 1987-10-16 1995-12-13 エラン コーポレーション ピー エル シー Diltiazem formulations with controlled absorption and methods for their production and use
KR900701255A (en) * 1988-11-30 1990-12-01 스테이너 브이.캔스타드 Sustained Release Diltiazem Formulations
US5229135A (en) * 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
WO1999020223A2 (en) * 1997-10-20 1999-04-29 Novo Nordisk A/S Luteinising hormone antagonists useful for treatment of estrogen deficiencies, or as a contraceptive
US6337091B1 (en) * 1997-10-27 2002-01-08 Temple University - Of The Commonwealth System Of Higher Education Matrix for controlled delivery of highly soluble pharmaceutical agents
PE20001396A1 (en) * 1999-01-18 2000-12-23 Gruenenthal Chemie DELAYED MEDICINAL FORMULATIONS CONTAINING A COMBINATION OF AN OPIOID OR A PHYSIOLOGICALLY TOLERABLE SALT OF THE SAME, AN O-AGONIST

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4404226A (en) * 1981-07-09 1983-09-13 Sandoz Ltd. Use of guanfacine in treating schizophrenia
US5246714A (en) * 1985-10-11 1993-09-21 Aktiebolaget Hassle Drug preparation
US4968508A (en) * 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
US5378474A (en) * 1989-01-06 1995-01-03 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5102668A (en) * 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
US5605911A (en) * 1995-01-31 1997-02-25 Washington University Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH)
US5854290A (en) * 1995-09-21 1998-12-29 Amy F. T. Arnsten Use of guanfacine in the treatment of behavioral disorders
US6245351B1 (en) * 1996-03-07 2001-06-12 Takeda Chemical Industries, Ltd. Controlled-release composition
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
US6811794B2 (en) * 2001-12-20 2004-11-02 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles

Cited By (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100008913A1 (en) * 1999-09-21 2010-01-14 Hanson Stephen R Methods and compositions for treating platelet-related disorders
US20040087486A1 (en) * 1999-09-21 2004-05-06 Hanson Stephen R. Methods and compositions for treating platelet-related disorders
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
US20060246003A1 (en) * 2004-12-27 2006-11-02 Eisai Co. Ltd. Composition containing anti-dementia drug
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
US20100152164A1 (en) * 2004-12-27 2010-06-17 Eisai R&D Management Co., Ltd. Method For Stabilizing Anti-Dementia Drug
US20080213368A1 (en) * 2004-12-27 2008-09-04 Eisai R & D Management Co., Ltd. Method for Stabilizing Anti-Dementia Drug
US8507527B2 (en) 2004-12-27 2013-08-13 Eisai R & D Management Co., Ltd. Method for stabilizing anti-dementia drug
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US8481565B2 (en) 2004-12-27 2013-07-09 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
US20060159753A1 (en) * 2004-12-27 2006-07-20 Eisai Co. Ltd. Matrix type sustained-release preparation containing basic drug or salt thereof
US20060160852A1 (en) * 2004-12-27 2006-07-20 Eisai Co. Ltd. Composition containing anti-dementia drug
US20090023778A1 (en) * 2005-04-28 2009-01-22 Eisai R&D Management Co., Ltd. Composition Containing Anti-Dementia Drug
WO2007054976A2 (en) * 2005-11-08 2007-05-18 Panacea Biotec Ltd. Lipid based controlled release pharmaceutical composition
WO2007054976A3 (en) * 2005-11-08 2007-08-09 Panacea Biotec Ltd Lipid based controlled release pharmaceutical composition
US7884122B2 (en) 2007-06-08 2011-02-08 Shionogi Pharma, Inc. Extended release formulation and method of treating adrenergic dysregulation
US20100172991A1 (en) * 2007-06-08 2010-07-08 Henry Joseph Horacek Extended Release Formulation and Methods of Treating Adrenergic Dysregulation
US20100209510A1 (en) * 2007-06-08 2010-08-19 Henry Joseph Horacek Extended Release Formulation and Method of Treating Adrenergic Dysregulation
US20090087490A1 (en) * 2007-06-08 2009-04-02 Addrenex Pharmaceuticals, Inc. Extended release formulation and method of treating adrenergic dysregulation
US20090324710A1 (en) * 2008-06-16 2009-12-31 Glidden Paul F Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
US9381198B2 (en) 2008-06-16 2016-07-05 Biovascular, Inc. Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
US9040483B2 (en) 2008-06-16 2015-05-26 Biovascular, Inc. Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
AT10562U3 (en) * 2008-12-05 2010-01-15 Aop Orphan Pharmaceuticals Ag A NEW COMPOSITION FOR TREATING AN ESSENCIAL THROMBOCYTEMIA
US11173123B2 (en) 2009-01-09 2021-11-16 Biogen Swiss Manufacturing Gmbh Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
US8906420B2 (en) 2009-01-09 2014-12-09 Forward Pharma A/S Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
WO2011085466A1 (en) 2010-01-18 2011-07-21 Medizone International Inc. Bio-terrorism counteraction using ozone and hydrogen peroxide
AU2011231557B2 (en) * 2010-03-25 2016-05-26 Aop Orphan Pharmaceuticals Ag Novel composition for treatment of essential thrombocythemia
EA027576B1 (en) * 2010-03-25 2017-08-31 Аоп Орфан Фармацойтикальс Аг Novel composition for treatment of essential thrombocythemia
WO2011117391A3 (en) * 2010-03-25 2012-01-19 Aop Orphan Pharmaceuticals Ag Novel composition for treatment of essential thrombocythemia
US9011912B2 (en) 2010-10-07 2015-04-21 Abon Pharmaceuticals, Llc Extended-release oral dosage forms for poorly soluble amine drugs
US9962345B2 (en) 2014-05-01 2018-05-08 Sun Pharmaceutical Industries Limited Oral liquid compositions of guanfacine
US9962336B2 (en) 2014-05-01 2018-05-08 Sun Pharmaceutical Industries Limited Extended release suspension compositions
US10258583B2 (en) 2014-05-01 2019-04-16 Sun Pharmaceutical Industries Limited Extended release liquid compositions of guanfacine
US11504345B2 (en) 2014-05-01 2022-11-22 Sun Pharmaceutical Industries Limited Extended release liquid compositions of metformin
US11523996B2 (en) 2014-05-01 2022-12-13 Sun Pharmaceutical Industries Limited Extended release liquid compositions of metformin
US10285908B2 (en) 2014-07-30 2019-05-14 Sun Pharmaceutical Industries Ltd Dual-chamber pack
WO2017182852A1 (en) * 2016-04-20 2017-10-26 Sun Pharmaceutical Industries Limited Extended release liquid compositions of guanfacine
US10238803B2 (en) 2016-05-02 2019-03-26 Sun Pharmaceutical Industries Limited Drug delivery device for pharmaceutical compositions
US10369078B2 (en) 2016-05-02 2019-08-06 Sun Pharmaceutical Industries Limited Dual-chamber pack for pharmaceutical compositions

Also Published As

Publication number Publication date
EP1351668A4 (en) 2007-01-31
US6287599B1 (en) 2001-09-11
PT1351668E (en) 2015-01-13
WO2002058676A1 (en) 2002-08-01
EP1351668A1 (en) 2003-10-15
JP2004518676A (en) 2004-06-24
CA2432178A1 (en) 2002-08-01
CA2432178C (en) 2010-04-20
EP1351668B1 (en) 2014-10-15
ES2527854T3 (en) 2015-01-30
AU2002249881B2 (en) 2006-12-21
JP4340840B2 (en) 2009-10-07
CY1116023T1 (en) 2017-01-25
DK1351668T3 (en) 2015-01-12

Similar Documents

Publication Publication Date Title
US6811794B2 (en) Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
CA2432178C (en) Sustained release pharmaceutical dosage forms with minimized ph dependent dissolution profiles
AU2002249881A1 (en) Sustained release pharmaceutical dosage forms with minimized PH dependent dissolution profiles
CN106943355B (en) Pharmaceutical composition
EP2397122B1 (en) Formulations of neramexane dosage forms
JPH061716A (en) Medical prescription having long-term releasability of active ingredient
CA2387621A1 (en) Extended release formulations of erythromycin derivatives
CN110876750A (en) Sustained-release composition containing ticagrelor or pharmaceutically acceptable salt thereof
KR20100020447A (en) Extended release formulation of nevirapine
AU2005256653B2 (en) Oral sustained release formulation of tedisamil with gastric retention properties
CA2616845A1 (en) Modified release tablet formulations with enhanced mechanical properties
WO2020138791A2 (en) Sustained-release preparation comprising tofacitinib or pharmaceutically acceptable salt thereof and manufacturing method therefor
EP2391353B1 (en) Pharmaceutical compositions of trimetazidine
AU2003253198A1 (en) Bicifadine formulation
WO2009043914A1 (en) Multi particulate matrix system containing galantamine
EP3335702A1 (en) Pharmaceutical compositions comprising omarigliptin
US20050142193A1 (en) Galantamine formulations
KR20190120092A (en) Oral Tablet Formulation of Lenalidomide with various doses
US20070104782A1 (en) Modified release tablet formulations with enhanced mechanical properties
EP2044933A1 (en) Multi particulate matrix system containing galantamine
EP3335703A1 (en) Pharmaceutical composition comprising omarigliptin
AU2006335344A1 (en) Controlled release formulation of divalproic acid and its derivatives
US20230172863A1 (en) Modified-release dosage forms of ruxolitinib
EP4251154A1 (en) Sustained release formulation compositions comprising propiverine
NZ760868B2 (en) A solid oral fixed dose composition comprising metformin, valsartan and atorvastatin

Legal Events

Date Code Title Description
AS Assignment

Owner name: SUPERNUS PHARMACEUTICALS, INC, MARYLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SHIRE LABORATORIES, INC;REEL/FRAME:017596/0304

Effective date: 20060425

STCB Information on status: application discontinuation

Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION